Journals / Türk Dermatoloji Dergisi / 2008 / Cilt: 2 - Sayı: 1

Drug reactions in dermatology

Dermatolojide ilaç reaksiyonları

Pages
1–5
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore patients should be informed about the responsible drug in a cutaneous drug eruption

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Skin is among the most important targets for drug reactions.
📊
Key Findings & Data:The study comprised 177 patients that were diagnosed with drug eruptions between 2003 and 2007.
💡
Conclusion & Impact:Therefore patients should be informed about the responsible drug in a cutaneous drug eruption
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Skin is among the most important targets for drug reactions. In patients hospitalized with a diagnosis of cutaneous drug eruptions, implicated drugs and related skin manifestations were evaluated in the light of literature data.Methods: This retrospective study was performed in Gazi University Medical Faculty, Department of Dermatology. The study comprised 177 patients that were diagnosed with drug eruptions between 2003 and 2007. Results: Of the 177 patients, 121 were women, 56 were men. The age of cases ranged between 8 and 83 years (mean age 45.5±18.5). Duration of the disease ranged from 1 to 60 days (mean 6.6±8.1). 54.8% of the patients had a systemic disease. Commonly implicated drugs were antibiotics, analgesics, antiinflammatory and antipyretic drugs, anticonvulsants, antineoplastics, antidepressants and antihypertension drugs. Urticaria/angioedema and maculopapular eruptions comprised 81.8% of eruptions.Conclusion: Cutaneous drug eruptions are mostly related to antibiotics, analgesics, antiinflammatory drugs, and antipyretics. Urticaria/angioedema and maculopapular drug eruptions are the most common forms. Anticonvulsants may cause severe reactions such as erythroderma and toxic epidermal necrolysis, therefore they must be used with concern. Some patients with cutaneous drug eruptions may define previous reactions to the same drug. Therefore patients should be informed about the responsible drug in a cutaneous drug eruption

Özet

Amaç: Deri ilaç reaksiyonlarında en önemli hedeflerden biridir. Bu çalışmada kutanöz ilaç reaksiyonu tanısı ile kliniğimizde yatırılan olgularda sorumlu ilaçlar ve bu ilaçların neden olduğu klinik tablolar literatür bilgileri eşliğinde değerlendirilmektedir.Yöntem: Çalışmaya 2003-2007 tarihleri arasında ilaç erüpsiyonu tanısı ile Gazi Üniversitesi Tıp Fakültesi Dermatoloji Kliniğinde yatırılarak tedavi edilen 177 olgu alınmıştır.Bulgular: Çalışmamızda yer alan 121’i kadın, 56’sı erkek 177 olgunun yaşları 8-83 arasında değişmekte olup ortalama 45.5±18.5’di. Hastalık süresi 1-60 gündü (ortalama 6.6±8.1). Olguların %54.8’inde sistemik bir hastalık bulunmaktaydı. Antibiyotikler, analjezik, antiinflamatuvar ve antipiretik ilaçlar, antikonvülzanlar, antineoplastikler, antidepresanlar, antihipertansifler en sık sorumlu olan ilaçlardı. Olguların %81.8’ini ürtiker/anjiyoödem ve makülopapüler ilaç erüpsiyonu oluşturuyordu. Sonuç: Kutanöz ilaç reaksiyonları büyük oranda antibiyotikler ve analjezik, antiinflamatuvar, antipiretik ilaçlardan kaynaklanmaktadır. Ürtiker/anjiyoödem ve makülopapüler erüpsiyonlar en sık görülen klinik formlardır. Eritrodermi ve toksik epidermal nekrolizis gibi ciddi hastalıklara yol açmaları nedeniyle antikonvülzanların dikkatli kullanılmaları gereklidir. Bu olguların bir kısmı öyküde aynı ilaçla benzer reaksiyonlar tanımlamaktadır. Kutanöz ilaç reaksiyonu tanısı konulan olgularda sorumlu ilaç hakkında hastanın bilgilendirilmesi gereklidir.

🔖

Cite This Article

ADIŞEN, E., KARACA, F., GÜRER, M. A. (2022). Drug reactions in dermatology. Türk Dermatoloji Dergisi, Cilt: 2 - Sayı: 1, 1–5. https://ajindex.com/articles/621658

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin 2007;25: 245-53
  2. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4: 561-72
  3. Roychowdhury S, Svensson CK. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J 2005;7: 834-46
  4. Anstey A. Drug reactions of the skin. Medicine 2005;33: 70-1
  5. Hernandez-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006;37: 899-902
  6. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med 1996;42: 15-22
  7. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209: 123-9
  8. Drug eruptions in children. Curr Probl Dermatol 2002;14: 147-82
  9. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001;137: 765-70
  10. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents-a 6 year series from Chandigarh, India. J Postgrad Med 2001;47: 95-9
  11. Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 2005;209: 201-7
  12. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003;149: 1018-22
  13. Apaydin R, Bilen N, Dokmeci S, et al. Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital. J Eur Acad Dermatol Venereol 2000;14: 518-20
  14. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006;31: 642-7
  15. Barbaud A, Reichert-Penetrat S, Trechot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998;139: 49-58
  16. Puavilai S, Choonhakarn C. Drug eruptions in Bangkok: a 1-year study at Ramathibodi Hospital. Int J Dermatol 1998; 37: 747-51
  17. Stubb S, Heikkila H, Kauppinen K. Cutaneous reactions to drugs: a series of in-patients during a five-year period. Acta Derm Venereol 1994;74: 289-91
  18. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986;256: 3358-63
  19. Sushma M, Noel MV, Ritika MC, et al. Cutaneous adverse drug re